摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(RS)-4,5-dihydro-4-methyl-1-phenyl-3-(2-phenylethyl)-1H-2,4-benzodiazepine | 142151-65-3

中文名称
——
中文别名
——
英文名称
(RS)-4,5-dihydro-4-methyl-1-phenyl-3-(2-phenylethyl)-1H-2,4-benzodiazepine
英文别名
4,5-Dihydro-4-methyl-1-phenyl-3-(2-phenylethyl)-1H-2,4-benzodiazepine;2-Methyl-5-phenyl-3-(2-phenylethyl)-1,5-dihydro-2,4-benzodiazepine
(RS)-4,5-dihydro-4-methyl-1-phenyl-3-(2-phenylethyl)-1H-2,4-benzodiazepine化学式
CAS
142151-65-3
化学式
C24H24N2
mdl
——
分子量
340.468
InChiKey
ULFIJMOTDRIEPH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    525.2±50.0 °C(Predicted)
  • 密度:
    1.06±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    15.6
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    D-二苯甲酰酒石酸(RS)-4,5-dihydro-4-methyl-1-phenyl-3-(2-phenylethyl)-1H-2,4-benzodiazepine甲醇 为溶剂, 生成 (R)-4,5-dihydro-4-methyl-1-phenyl-3-(2-phenylethyl)-1H-2,4-benzodiazepine dibenzoyl-D-tartarate
    参考文献:
    名称:
    4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents
    摘要:
    A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 muM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for vertricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.
    DOI:
    10.1021/jm00074a017
  • 作为产物:
    描述:
    Triethyl-3-phenyl-propionylorthoformat 、 N-methyl-α'-phenyl-1,2-phenylenedimethanamine dihydrochloride 在 sodium acetate溶剂黄146 作用下, 反应 24.0h, 生成 (RS)-4,5-dihydro-4-methyl-1-phenyl-3-(2-phenylethyl)-1H-2,4-benzodiazepine
    参考文献:
    名称:
    4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents
    摘要:
    A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 muM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for vertricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.
    DOI:
    10.1021/jm00074a017
点击查看最新优质反应信息

文献信息

  • Aryl-fused and hetaryl-fused-2, 4-diazepine and 2, 4-diazocine antiarrhythmic agents
    申请人:STERLING DRUG INC.
    公开号:EP0475527A2
    公开(公告)日:1992-03-18
    Aryl-fused- and hetaryl-fused-2,4-diazepines of formula XXXVI, benzodiazocines of formula XXX, benzodiazepines of formula II δ-aminoamides of formula III and aryldimethanamines of formula XXXVII wherein Ais an aryl, alicyclic or or hetaryl ring; R¹is hydrogen, alkyl, aryl or hetaryl; R²is hydrogen, alkyl, substituted alkyl, or aryl; R³is hydrogen, alkyl, aryl, aralkyl, hetaryl or heteroatom substituted alkyl or aralkyl; R⁴is hydrogen, alkyl or substituted alkyl; R⁵is hydrogen, alkyl, aryl or hetaryl; R⁶is hydrogen, alkyl, alkoxy, nitro, alkylsulfonamido, halogen or a fused benzene ring; R⁹is hydrogen, alkyl, substituted alkyl or aralkyl; and R¹⁰is hydrogen, alkyl, substituted alkyl, aryl or hetaryl. This invention further relates to processes for the preparation of, pharmaceutical compositions containing, and methods of treating cardiac arrhythmia with the compounds of formulae XXXVI, XXX, II, III, and XXXVII.
    式 XXXVI 的芳基融合-和正十八烷基融合-2,4-二氮杂卓、式 XXX 的苯并二氮杂卓、式 II 的苯并二氮杂卓 式 III 的δ-氨基酰胺和式 XXXVII 的芳基二甲胺 其中 A 是芳基环、脂环或正庚基环; R¹是氢、烷基、芳基或正十八烷基; R² 是氢、烷基、取代烷基或芳基; R³ 是氢、烷基、芳基、芳烷基、正烷基或杂原子取代的烷基或芳烷基; R⁴ 是氢、烷基或取代的烷基; R⁵ 是氢、烷基、芳基或正十八烷基; R⁶ 是氢、烷基、烷氧基、硝基、烷基磺酰胺基、卤素或融合苯环; R𠞙 是氢、烷基、取代烷基或芳烷基;以及 R¹⁰是氢、烷基、取代烷基、芳基或正烷基。 正十八烷基。 本发明进一步涉及用式 XXXVI、XXX、II、III 和 XXXVII 的化合物制备心律失常的工艺、含有这些化合物的药物组合物以及治疗心律失常的方法。
  • Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
    申请人:SANOFI
    公开号:EP0475527B1
    公开(公告)日:1998-02-25
  • JPH05339246A
    申请人:——
    公开号:JPH05339246A
    公开(公告)日:1993-12-21
  • US5380721A
    申请人:——
    公开号:US5380721A
    公开(公告)日:1995-01-10
  • 4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents
    作者:Robert E. Johnson、Eugene R. Baizman、Carolyn Becker、Eric A. Bohnet、Rebecca H. Bell、Nancy C. Birsner、Carl A. Busacca、Philip M. Carabateas、Christopher C. Chadwick
    DOI:10.1021/jm00074a017
    日期:1993.10
    A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 muM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for vertricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.
查看更多